Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jagadeesh Aluri

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
CPT: Pharmacometrics & Systems Pharmacology|March 26, 2024
Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC)Oneeb Majid, Seiichi Hayato, Sree Harsha Sreerama Reddy, et al.
British Journal of Clinical Pharmacology|January 18, 2018
Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugsMaiko Nomoto, Cynthia A Zamora, Edgar Schuck, et al.
Clinical Pharmacology in Drug Development|October 11, 2022
First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll-like Receptors 7 and 8, in Healthy VolunteersNaoto Yamakawa, Fumitoshi Tago, Kenya Nakai, et al.
Alzheimer'S Research & Therapy|April 10, 2026
Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairmentErica Andreozzi, Takuya Yagi, Kristin Wildsmith, et al.
Pediatric Blood & Cancer|May 2, 2025
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid TumorsFilemon S Dela Cruz, Elizabeth Fox, Steven G DuBois, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
CPT: Pharmacometrics & Systems Pharmacology|March 26, 2024
Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC)Oneeb Majid, Seiichi Hayato, Sree Harsha Sreerama Reddy, et al.
British Journal of Clinical Pharmacology|January 18, 2018
Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugsMaiko Nomoto, Cynthia A Zamora, Edgar Schuck, et al.
Clinical Pharmacology in Drug Development|October 11, 2022
First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll-like Receptors 7 and 8, in Healthy VolunteersNaoto Yamakawa, Fumitoshi Tago, Kenya Nakai, et al.
Alzheimer'S Research & Therapy|April 10, 2026
Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairmentErica Andreozzi, Takuya Yagi, Kristin Wildsmith, et al.
Pediatric Blood & Cancer|May 2, 2025
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid TumorsFilemon S Dela Cruz, Elizabeth Fox, Steven G DuBois, et al.
Pageof 4